Wesley Winn

Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA.

Dendreon Pharmaceuticals LLC is a commercial-stage biopharmaceutical company that specializes in developing, manufacturing, and commercializing cell therapies. Dendreon Pharmaceuticals is based in Seal Beach, CA. The private company is a pioneer in cellular therapy, targeting cancer and transforming lives. Dendreon has proven expertise in cellular therapy and ensures product quality through its experience in the field. The company was founded in 1992 by Edgar G. Engleman and Samuel Strober, and the CEO is John C O'Neill.

Micronoma, Inc. is a cancer-detection company that uses signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma is headquartered in San Diego, CA. The company aims to revolutionize and advance the practice of early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients' needs are identified and addressed by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company was founded in 2019 by Sandrine Miller-Montgomery, Greg Poore, Rob Knight, and Magda Marquet. Sandrine Miller-Montgomery has been the CEO since 2019.

Symbiosis Capital Management LLC (SymBiosis) is a venture capital firm founded in 2019. The firm is headquartered in Bentonville, Arkansas.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.

Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The company is based in New York, NY.